Related Experiment Videos
Acute promyelocytic leukemia toluidine blue subtype
R Invernizzi1, A M Iannone, S Bernuzzi
1Dipartimento di Medicina Interna, IRCCS Policlinico San Matteo, Pavia, Italy.
Leukemia & Lymphoma
|January 1, 1995
Summary
A rare variant of acute promyelocytic leukemia (APL) with basophilic granules was identified in 19% of patients. This subtype presents unique morphological and cytochemical features, impacting clinical significance and diagnosis.
Area of Science:
- Hematology
- Oncology
- Cell Biology
Background:
- Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia.
- A rare hypergranular variant of APL with basophilic granules has been recognized.
- The biological and clinical significance of this subtype requires further investigation.
Purpose of the Study:
- To determine the incidence of the basophilic granular subvariant of APL.
- To evaluate the biological and clinical significance of this APL subtype.
- To identify diagnostic markers differentiating this subtype from other leukemias.
Main Methods:
- Morphological, cytochemical, immunological, and cytogenetic analyses were performed on 53 untreated APL patients.
- Toluidine blue staining was used to identify metachromatic granules.
- Peroxidase and esterase activities were assessed, alongside ultrastructural examination.
Main Results:
- 19% of APL cases (10 out of 53) exhibited metachromatic basophilic granules.
- This subtype showed weaker peroxidase positivity and usually present esterase activities.
- Immunophenotypic and cytogenetic profiles did not significantly differ from other APL subtypes.
- Coagulopathy was severe, and median survival was short, despite low white cell counts.
Conclusions:
- The basophilic granular subvariant of APL occurs in 19% of cases and has distinct morphological and cytochemical characteristics.
- While immunophenotypic and cytogenetic features are similar to classic APL, clinical outcomes can be severe.
- Cytochemical, immunologic, and cytogenetic findings are crucial for differentiating this APL subtype from M2 leukemia and mast cell leukemia.